Jamie Rossjohn

Professor, Monash University
  • Monash University
  • Members
  • Australia

About Jamie Rossjohn

Professor Jamie Rossjohn’s research is centered on an understanding immunity. He is currently an ARC Australian Laureate Fellow (2017-2021) and previously a NHMRC Australia Fellow (2011-2016) and ARC Federation Fellow (2007-11). Prof. Rossjohn is known for his contributions to the understanding the molecular basis underpinning immunity. He has used structural biology to explain pre-T- cell receptor (TCR) self-association in T-cell development, and how the TCR specifically recognises polymorphic Human Leukocyte Antigen (HLA) molecules in the context of viral immunity and aberrant T- cell reactivity. He has unearthed structural mechanisms of HLA polymorphism impacting on drug and food hypersensitivities, as well as Natural Killer cell receptor recognition. He has pioneered our molecular understanding of lipid-based immunity by T cells, revealing that it can differ fundamentally from peptide-mediated adaptive immunity. Recently he has provided a structural basis of how vitamin B metabolites can be presented and recognised by the immune system, revealing a new class of antigen. Collectively, he has published > 400 papers and mentored numerous researchers towards obtaining higher degrees and nationally competitive fellowships.

Intro Content

Contributor Nature Cancer

A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent anti-tumor response

The type 1 NKT cell stimulating glycolipid α-galactosylceramide (α-GalCer) was first identified by the Pharmaceutical Research Laboratory of Kirin Brewery in a screen for novel anti-tumor agents. Based on promising preclinical data it was tested as an anticancer drug in multiple clinical studies.

Popular Content

Topics

Channels contributed to:

Behind the paper